PMID- 23640554
OWN - NLM
STAT- MEDLINE
DCOM- 20131231
LR  - 20231106
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 137
IP  - 3
DP  - 2013 Mar
TI  - Tuberculosis: From an incurable scourge to a curable disease - journey over a 
      millennium.
PG  - 455-93
AB  - Globally, tuberculosis (TB) still remains a major public health problem. India is 
      a high TB burden country contributing to 26 per cent of global TB burden. During 
      1944-1980, TB became treatable and short-course chemotherapy emerged as the 
      standard of care. When TB elimination seemed possible in the early 1980s, global 
      human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome 
      (AIDS) pandemic resulted in a resurgence of TB. Widespread occurrence of 
      multidrug-resistant and extensively drug-resistant TB (M/XDR-TB) is threatening 
      to destabilize TB control globally. Atypical clinical presentation still poses a 
      challenge. Disseminated, miliary and cryptic TB are being increasingly 
      recognized. Availability of newer imaging modalities has allowed more efficient 
      localization of lesions and use of image guided procedures has facilitated 
      definitive diagnosis of extrapulmonary TB. Introduction of liquid culture, rapid 
      drug-susceptibility testing (DST), molecular diagnostic methods has helped in 
      rapid detection, speciation and DST profiling of Mycobacterium tuberculosis 
      isolates. While treatment of TB and HIV-TB co-infection has become simpler, 
      efforts are on to shorten the treatment duration. However, drug toxicities and 
      drug-drug interactions still constitute a significant challenge. Recently, there 
      has been better understanding of anti-TB drug-induced hepatotoxicity and its 
      frequent confounding by viral hepatitis, especially, in resource-constrained 
      settings; and immune reconstitution inflammatory syndrome (IRIS) in HIV-TB. Quest 
      for newer biomarkers for predicting a durable cure, relapse, 
      discovery/repurposing of newer anti-TB drugs, development of newer vaccines 
      continues to achieve the goal of eliminating TB altogether by 2050.
FAU - Sharma, Surendra K
AU  - Sharma SK
AD  - Department of Medicine, All India Institute of Medical Sciences, New Delhi, 
      India. sksharma@aiims.gmail.com
FAU - Mohan, Alladi
AU  - Mohan A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Antitubercular Agents/*therapeutic use
MH  - Coinfection
MH  - HIV Infections/complications/drug therapy/*epidemiology/microbiology
MH  - Humans
MH  - India
MH  - Tuberculosis, Multidrug-Resistant/complications/*drug 
      therapy/*epidemiology/pathology
PMC - PMC3705655
EDAT- 2013/05/04 06:00
MHDA- 2014/01/01 06:00
PMCR- 2013/03/01
CRDT- 2013/05/04 06:00
PHST- 2013/05/04 06:00 [entrez]
PHST- 2013/05/04 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
PHST- 2013/03/01 00:00 [pmc-release]
AID - IndianJMedRes_2013_137_3_455_110999 [pii]
AID - IJMR-137-455 [pii]
PST - ppublish
SO  - Indian J Med Res. 2013 Mar;137(3):455-93.